Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable ...
BEVERLY, MA--(Marketwired - February 22, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic …